A5033079310- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Viral-associated cancers and disorders
- CAR-T cell therapy research
- Acute Myeloid Leukemia Research
- Cancer Genomics and Diagnostics
- CNS Lymphoma Diagnosis and Treatment
- Sarcoma Diagnosis and Treatment
- Immune Cell Function and Interaction
- Ovarian cancer diagnosis and treatment
- T-cell and Retrovirus Studies
- Lung Cancer Treatments and Mutations
- Monoclonal and Polyclonal Antibodies Research
- Vascular Tumors and Angiosarcomas
- Acute Lymphoblastic Leukemia research
- Cutaneous lymphoproliferative disorders research
- Chronic Myeloid Leukemia Treatments
- Genetic factors in colorectal cancer
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Thyroid Cancer Diagnosis and Treatment
- Histone Deacetylase Inhibitors Research
- Epigenetics and DNA Methylation
- Viral Infectious Diseases and Gene Expression in Insects
- Cancer-related gene regulation
- Exercise and Physiological Responses
Ludwig-Maximilians-Universität München
2016-2025
Zimmer Biomet (Germany)
2016-2025
LMU Klinikum
2015-2025
München Klinik
2011-2024
Zimmer Biomet (Netherlands)
2022-2024
Institut für Medizinische Informatik, Biometrie und Epidemiologie
2018-2023
Palmetto Hematology Oncology
2022
Roche (Bosnia-Herzegovina)
2018
Addenbrooke's Hospital
2017
University of Minnesota
2017
Purpose Mantle cell lymphoma (MCL) is characterized by a poor prognosis with low to moderate sensitivity chemotherapy and median survival of only 3 4 years. In an attempt improve outcome, the German Low Grade Lymphoma Study Group (GLSG) initiated randomized trial comparing combination cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) rituximab (R-CHOP) CHOP alone as first-line therapy for advanced-stage MCL. Patients Methods One hundred twenty-two previously untreated patients...
The long-term prognosis for older patients with mantle-cell lymphoma is poor. Chemoimmunotherapy results in low rates of complete remission, and most have a relapse. We investigated whether fludarabine-containing induction regimen improved the complete-remission rate maintenance therapy rituximab prolonged remission.We randomly assigned 60 years age or lymphoma, stage II to IV, who were not eligible high-dose six cycles rituximab, fludarabine, cyclophosphamide (R-FC) every 28 days eight...
Mantle cell lymphomas (MCLs) represent a clinically aggressive lymphoma subtype with poor prognosis. To explore potential progress in outcome historical comparison was performed using data from the Kiel Lymphoma Study Group (KLSG; 1975 to 1986) and German Low Grade (GLSG; 1996 2004).All patients histologically confirmed diagnosis of advanced-stage nonblastoid MCL were eligible. minimize heterogeneity different risk profiles frequency matching pursued. In addition, we adjusted for confounding...
Mantle-cell lymphoma (MCL) is a rather aggressive B-cell malignancy whose considerable variability of individual outcome associated with clinical characteristics (Mantle Cell Lymphoma International Prognostic Index [MIPI]). The Ki-67 index strong independent prognostic factor; however, the biologic MIPI (MIPI-b) distinguishes only two groups, which does not appropriately depict heterogeneity. By using cohort from European MCL Younger and Elderly trials, we aimed to evaluate additional impact...
CEBPA mutations are found as either biallelic (biCEBPA) or monoallelic (moCEBPA). We set out to explore whether the kind of mutation is prognostic relevance in cytogenetically normal (CN) acute myeloid leukemia (AML).Four hundred sixty-seven homogeneously treated patients with CN-AML were subdivided into moCEBPA, biCEBPA, and wild-type (wt) patients. The subgroups analyzed for clinical parameters additional NPM1, FLT3, MLL genes. Furthermore, we obtained gene expression profiles using...
MYC rearrangement (MYC-R) occurs in approximately 10% of diffuse large B-cell lymphomas (DLBCLs) and has been associated with poor prognosis many studies. The impact MYC-R on may be influenced by the partner gene (immunoglobulin [IG] or a non-IG gene). We evaluated cohort patients through Lunenburg Lymphoma Biomarker Consortium to validate prognostic significance (single-, double-, triple-hit status) DLBCL within context gene.The study included histologically confirmed morphology derived...
<h3>Background</h3> CD19-directed chimeric antigen receptor T-cell therapy (CAR-T) represents a promising treatment modality for an increasing number of B-cell malignancies. However, prolonged cytopenias and infections substantially contribute to the toxicity burden CAR-T. The recently developed CAR-HEMATOTOX (HT) score—composed five pre-lymphodepletion variables (eg, absolute neutrophil count, platelet hemoglobin, C-reactive protein, ferritin)—enables risk stratification hematological...
BackgroundAdding ibrutinib to standard immunochemotherapy might improve outcomes and challenge autologous stem-cell transplantation (ASCT) in younger (aged 65 years or younger) mantle cell lymphoma patients. This trial aimed investigate whether the addition of results a superior clinical outcome compared with pre-trial ASCT an ibrutinib-containing treatment without ASCT. We also investigated is adding but ASCT.MethodsThe open-label, randomised, three-arm, parallel-group, superiority TRIANGLE...
Mantle cell lymphoma (MCL) has a heterogeneous clinical course and is mainly an aggressive B non-Hodgkin lymphoma; however, there are some indolent cases The Ki-67 index, defined by the percentage of Ki-67-positive cells on histopathological slides, been shown to be very powerful prognostic biomarker. pathology panel European MCL Network evaluated methods assess index including stringent counting, digital image analysis, estimation eyeballing. Counting 2 × 500 gold standard since this value...
Mantle-cell lymphoma (MCL) is a distinct B-cell associated with poor outcome. In 2008, the MCL International Prognostic Index (MIPI) was developed as first prognostic stratification tool specifically directed to patients MCL. External validation planned be performed on cohort of two recently completed randomized trials European Network.Data 958 (median age, 65 years; range, 32 87 years) treated upfront in Younger or Elderly were pooled assess value MIPI respect overall survival (OS) and time...